Amino Nitrogen Attached To The Carbon By An Acyclic Carbon Or Chain Patents (Class 564/316)
-
Publication number: 20090062398Abstract: The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 21, 2008Publication date: March 5, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090018207Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.Type: ApplicationFiled: September 19, 2008Publication date: January 15, 2009Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7462742Abstract: An in situ or one-pot process for the preparation of the compounds of formula (I) uses a compound of general formula (I): and includes: a) the hydrogenation of a nitrile group of the compound of general formula (II): in which R1 to R4 are especially H or alkyl and n varies from 0 to 4, in the presence of a hydrogenation catalyst, a methylating agent and an organic acid as solvent, and at a temperature Ta below the initiation temperature of a reductive amination reaction, to give a primary amine from the nitrile group; and b) the reductive amination of the primary amine in the presence of hydrogen, at a temperature Tb above Ta, to give the dimethylated amine of general formula (I) by activation of the methylating age.Type: GrantFiled: January 23, 2007Date of Patent: December 9, 2008Assignee: Zach SystemInventors: Alain Burgos, Jacques Tonnel, Valéry Dambrin, Denis Lucet, Patricia Poirier
-
Patent number: 7456222Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: July 1, 2005Date of Patent: November 25, 2008Assignees: Sequella, Inc., The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
-
Publication number: 20080234516Abstract: Provided are processes for the preparation of amorphous O-desmethylvenlafaxine and for the preparation of crystalline forms I, II, III, and IV of O-desmethylvenlafaxine.Type: ApplicationFiled: March 14, 2008Publication date: September 25, 2008Inventors: Valerie Niddam-Hildesheim, Sharona Shachan-Tov, Yaron Shmuely, Tamar Nidam, Alexandr Jegorov
-
Patent number: 7420091Abstract: A novel process for the preparation of tolterodine, i.e. (R)—N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.Type: GrantFiled: December 14, 2007Date of Patent: September 2, 2008Assignee: Dipharma S.p.A.Inventors: Gabriele Razzetti, Simone Mantegazza, Roberto Rossi, Pietro Allegrini
-
Publication number: 20080188684Abstract: Described is a process of preparing a pure solid or crystalline racemic 3,3-diarylpropylamine compound and the compounds formed thereof. The solid and crystalline forms of racemic 3,3-diarylpropylamine compound are especially suitable for producing highly pure 3,3-diarylpropylamine salts such as tolterodine tartrate. Also described are the highly pure solid or crystalline forms of racemic tolterodine, racemic tolterodine salt and tolterodine tartrate.Type: ApplicationFiled: November 27, 2007Publication date: August 7, 2008Inventors: Maria Angeles Conde Martinez, Ignasi Auquer i Pedemonte
-
Publication number: 20080183016Abstract: Provided are processes and intermediates for the synthesis of O-desmethylvenlafaxine.Type: ApplicationFiled: July 26, 2007Publication date: July 31, 2008Inventors: Valerie Niddam-Hildesheim, Tamar Nidam
-
Publication number: 20080177110Abstract: Provides are intermediates and processes for preparation of o-desmethylvenlafaxine.Type: ApplicationFiled: July 26, 2007Publication date: July 24, 2008Inventors: Valerie Niddam-Hildesheim, Tamar Nidam
-
Patent number: 7393874Abstract: The present invention relates to novel polymorphs of tolterodine tartrate, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: April 8, 2003Date of Patent: July 1, 2008Assignee: Hetero Drugs LimitedInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Kesireddy Subash Chander Reddy
-
Publication number: 20080146844Abstract: A process for preparing tolterodine with high purity.Type: ApplicationFiled: January 28, 2008Publication date: June 19, 2008Applicants: DR. REDDY'S LABORATORIES LIMITED, DR. REDDY'S LABORATORIES, INC.Inventors: Sundaram Venkataraman, Vijayavitthal Thippannachar Mathad, Kikkuru Srirami Reddy, Neti Srinivasan, Chinta Raveendra Reddy, Muthulingam Arunagiri, Routhu Lalitha Kumari
-
Publication number: 20080125606Abstract: An in situ or one-pot process for the preparation of the compounds of formula (I) uses a compound of general formula (I): and includes: a) the hydrogenation of a nitrile group of the compound of general formula (II): in which R1 to R4 are especially H or alkyl and n varies from 0 to 4, in the presence of a hydrogenation catalyst, a methylating agent and an organic acid as solvent, and at a temperature Ta below the initiation temperature of a reductive amination reaction, to give a primary amine from the nitrile group; and b) the reductive amination of the primary amine in the presence of hydrogen, at a temperature Tb above Ta, to give the dimethylated amine of general formula (I) by activation of the methylating age.Type: ApplicationFiled: January 23, 2007Publication date: May 29, 2008Applicant: PPG-SIPSYInventors: Alain Burgos, Jacques Tonnel, Valerie Dambrin, Denis Lucet, Patricia Poirier
-
Patent number: 7358399Abstract: A process is described for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine comprising substitution of the sulfonyloxy group of the compound of the formula in which the substituents R and R? have the meanings stated in the description, in a solvent comprising an ionic liquid, to yield the tertiary amine of the formula and the subsequent deprotection thereof.Type: GrantFiled: October 6, 2005Date of Patent: April 15, 2008Assignee: Chemi SPAInventors: Stefano Turchetta, Umberto Ciambecchini, Pietro Massardo
-
Patent number: 7355077Abstract: A process for preparing tolterodine with high purity.Type: GrantFiled: October 26, 2005Date of Patent: April 8, 2008Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Sundaram Venkataraman, Vijayavitthal Thippannachar Mathad, Kikkuru Srirami Reddy, Neti Srinivasan, Chinta Raveendra Reddy, Muthulingam Arunagiri, Routhu Lalitha Kumari
-
Patent number: 7355079Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 5, 2005Date of Patent: April 8, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Motonori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Patent number: 7339079Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: June 17, 2005Date of Patent: March 4, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow
-
Patent number: 7335793Abstract: A novel process prepares tolterodine, i.e. (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation. Tolterodine free base may be prepared by reacting diisopropyl-(3-phenyl-3-p-tolyloxy-propyl)-amine and 60% aqueous sulfuric acid for three hours under stirring at room temperature. The reaction mixture is then poured over ice/water and then alkalized with 50% NaOH.Type: GrantFiled: February 21, 2006Date of Patent: February 26, 2008Assignee: Dipharma S.p.A.Inventors: Gabriele Razzetti, Simone Mantegazza, Roberto Rossi, Pietro Allegrini
-
Patent number: 7321065Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 16, 2004Date of Patent: January 22, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Motonori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Patent number: 7291648Abstract: Novel 3,3-diphenylpropylamines of the formula and stereoisomers and physiologically acceptable acid addition salt thereof; wherein R1, R2, R3, R4, R5, and R6 are as defined herein; methods of use thereof; and pharmaceutical compositions thereof.Type: GrantFiled: August 24, 2006Date of Patent: November 6, 2007Assignee: Pfizer Inc.Inventors: John Gregory Slatter, Raymond Charles Grabiak, Robert John Kaufman
-
Patent number: 7268257Abstract: The present invention provides a process for producing tolterodine of the formula (1) or its salt, which comprises a step reacting a compound of the formula (2) with a base to obtain a reaction product; a step reacting the reaction product with a compound of the formula (3) to obtain a compound of the formula (4); and a step eliminating the protective group from the compound of the formula (4), and also provides a process for producing the compound of the formula (3).Type: GrantFiled: May 31, 2006Date of Patent: September 11, 2007Assignee: Sumitomo Chemical Company, LimitedInventors: Tsukusa Yamada, Nobushige Itaya, Masahide Tanaka
-
Patent number: 7268166Abstract: Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).Type: GrantFiled: February 13, 2006Date of Patent: September 11, 2007Assignee: NPS Pharmaceuticals, Inc.Inventors: Alan L. Mueller, Scott T. Moe
-
Patent number: 7230030Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: GrantFiled: January 27, 2004Date of Patent: June 12, 2007Assignee: Schwarz Pharma AGInventors: Claus Meese, Bengt Sparf
-
Patent number: 7141696Abstract: The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, and other smooth muscle contractility conditions. More particularly, the present invention relates to certain metabolically stabilized secondary amines having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects.Type: GrantFiled: May 21, 2004Date of Patent: November 28, 2006Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, Jan L. Chen, Andrew T. Maioli, George E. Wright
-
Patent number: 7126028Abstract: Process for the preparation of chiral compounds of formula (I) comprising contacting a compound of formula (II) with a source of hydrogen or halide; wherein A is a chiral center; X is selected from oxygen, sulphur and nitrogen; n is selected from 0 and 1 and is equal to the valence of X less 2; B is a fragment CR 3 2; Z is hydrogen or halogen; with the proviso that when X is nitrogen, n is 1, one of R 1 and two of R 2 are hydrogen, BZ is CHPh 2, the other R 1 and R 2 do not form together a five membered heterocyclic (pyrrolidone) ring; novel intermediates, novel compounds, polymers and libraries thereof and the use thereof as fine chemicals, and compositions thereof.Type: GrantFiled: December 6, 1999Date of Patent: October 24, 2006Assignee: The University Court of the University of St. AndrewsInventor: David O'Hagan
-
Patent number: 7119121Abstract: Novel 3,3-diphenylpropylamines of the formula and stereoisomers and physiologically acceptable acid addition salt thereof; wherein R1, R2, R3, R4, R5, and R6 are as defined herein; methods of use thereof; and pharmaceutical compositions thereof.Type: GrantFiled: August 25, 2005Date of Patent: October 10, 2006Assignee: Pfizer Inc.Inventors: John Gregory Slatter, Raymond Charles Grabiak, Robert John Kaufman
-
Patent number: 7119212Abstract: A process for the preparation of 6-methyl-4-(R)-phenyl-chroman-2-one and 6-methyl-4-(S)-phenyl-chroman-2-one, intermediates for the synthesis of tolterodine and its (S) enantiomer, by reaction of 6-methyl-coumarin with phenylboronic acids, esters and derivatives thereof, in the presence of chiral catalysts.Type: GrantFiled: March 29, 2005Date of Patent: October 10, 2006Assignee: Dipharma S.p.A.Inventors: Lino Colombo, Roberto Rossi, Pietro Allegrini, Graziano Castaldi
-
Patent number: 7078567Abstract: The present invention provides methodology for carbon-nitrogen bond formation via vinyl or aryl amination. In the process of the invention, an sp2 hybridized radical is reacted with an azomethine moiety to form pyrrolidine and indole compounds. The methodology provides a facile process for the synthesis of compounds having the pyrrolidine or indole subunit and is especially advantageous for compounds having acid or base labile functional groups and/or is comprised of chiral centers susceptible to acid/base epimerization.Type: GrantFiled: October 16, 2003Date of Patent: July 18, 2006Inventors: Jeffrey N. Johnston, Rajesh Viswanathan
-
Patent number: 6822119Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 18, 2004Date of Patent: November 23, 2004Assignee: Ranbaxy Laboratories LimitedInventors: Yatendra Kumar, Mohan Prasad, Praveen Kumar Neela, Satyananda Misra
-
Patent number: 6759435Abstract: Novel amines are potent and selective serotonin reuptake inhibitors and as such can be used in the treatment of depression and other mental disorders.Type: GrantFiled: July 3, 2003Date of Patent: July 6, 2004Assignee: A.P. Group Inc.Inventor: Larry Chen
-
Patent number: 6713464Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: GrantFiled: January 2, 2001Date of Patent: March 30, 2004Assignee: Schwarz Pharma AGInventors: Claus Meese, Bengt Sparf
-
Publication number: 20030236309Abstract: A novel salt of O-desmethylvenlafaxine, O-desmethylvenlafaxine formate, is provided. Pharmaceutical compositions, dosage forms and methods of use are also provided.Type: ApplicationFiled: June 9, 2003Publication date: December 25, 2003Applicant: WyethInventors: Anthony Francis Hadfield, Michael William Winkley
-
Publication number: 20030191347Abstract: Venlafaxine base is obtained in pharmaceutically useful form. Two crystal forms of venlafaxine base are identified and a process of precipitating solid venlafaxine base is provided.Type: ApplicationFiled: March 27, 2003Publication date: October 9, 2003Inventors: Rolf Keltjens, Frantisek Picha, Juan Cucala Escoi
-
Publication number: 20030191348Abstract: The invention relates to a process for the enantioselective preparation of tolterodine and analogues and salts thereof comprises the steps of:Type: ApplicationFiled: March 28, 2003Publication date: October 9, 2003Inventors: Pher G. Andersson, Christian Hedberg
-
Publication number: 20030148201Abstract: Disclosed are a novel organic photoconductive material suitable as a charge-transporting material in a photosensitive layer of an electrophotographic photoreceptor or usable in various display devices, and an electrophotographic photoreceptor which uses the above organic photoconductive material in a photosensitive layer and which exhibits a high charge potential and high sensitivity and also exhibits little or almost no change in various properties in repeated use and can exhibit stabilized performances.Type: ApplicationFiled: October 21, 2002Publication date: August 7, 2003Inventors: Tatsuya Kodera, Koichi Torizuka
-
Publication number: 20030114711Abstract: Disclosed is a process for the preparation of a compound of formula 1Type: ApplicationFiled: October 15, 2002Publication date: June 19, 2003Inventors: Niranjan Paingankar, Vilas Mumbaikar, Vadiraj S Ekkundi, Hans-Peter Jalett, Urs Siegrist, Paul Adriaan Van Der Schaaf, Frank Bienewald, Martin Studer, Stefan Burkhardt
-
Publication number: 20030114536Abstract: This invention relates to novel crystalline polymorphic form of venlafaxine hydrochloride which exists in hydrated form (e.g., as a monohydrate), methods for the preparation thereof, and its use.Type: ApplicationFiled: December 3, 2002Publication date: June 19, 2003Applicant: WyethInventors: Jun Han, Yong Jai Lee
-
Publication number: 20030109585Abstract: This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use.Type: ApplicationFiled: December 3, 2002Publication date: June 12, 2003Applicant: WyethInventors: Kadum Abdul Nabi Ali, Jun Han, Yong Jai Lee
-
Patent number: 6518314Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.Type: GrantFiled: October 6, 2000Date of Patent: February 11, 2003Assignee: Nymox CorporationInventors: Paul Averback, Hossein Ghanbari, Iraj Beheshti, David Morse
-
Publication number: 20020183553Abstract: The present invention relates to novel essentially pure venlafaxine and the process of preparation thereof. The present invention also relates to novel solvate forms of venlafaxine hydrochloride and the process of preparation thereof. Furthermore, the present invention provides a novel process for preparing venlafaxine hydrochloride from venlafaxine; the process comprises the steps of: i) preparing a mixture of venlafaxine with acetone; and ii) exposing the mixture in gaseous hydrochloric acid.Type: ApplicationFiled: November 30, 2001Publication date: December 5, 2002Inventors: Ben-Zion Dolitzky, Judith Aronhime, Shlomit Wizel, Gennady A. Nisnevich
-
Publication number: 20020143211Abstract: The present invention relates to novel essentially pure venlafaxine and the process of preparation thereof. The present invention also relates to novel solvate forms of venlafaxine hydrochloride and the process of preparation thereof. Furthermore, the present invention provides a novel process for preparing venlafaxine hydrochloride from venlafaxine; the process comprises the steps of: I) preparing a mixture of venlafaxine with acetone; and ii) exposing the mixture in gaseous hydrochloric acid.Type: ApplicationFiled: October 19, 2001Publication date: October 3, 2002Inventors: Ben-Zion Dolitzky, Judith Aronhime, Shlomit Wizel, Gennady Nisnevish
-
Patent number: 6440440Abstract: This invention concerns compounds of formula. stereochemically isomeric forms thereof, acid or base addition salts thereof, N-oxides thereof, or quaternary ammonium derivatives thereof, wherein the dotted line is an optional bond; X is a direct bond when the dotted line represents a bond, or X is hydrogen or hydroxy, when the dotted line does not represent a bond; R1, R2, R5 and R6 are each independently selected from hydrogen, halo, hydroxy, C1-4alkyl, C1-4alkyloxy, —SO3H, and the like; R3 and R4 are each independently selected from hydrogen, halo, hydroxy, C1-4alkyl, C1-4alkyloxy, nitro, amino, cyano, trifluoromethyl, or trifluoromethoxy; L is a radical of formula wherein A1 is a direct bond or C1-6alkanediyl; A2 is C2-6alkanediyl; and R7 to R11 are hydrogen, C1-6alkyl, aminoC1-6alkyl and the like; having biocidal properties; their preparation, compositions containing them and their use as a biocide.Type: GrantFiled: September 22, 2000Date of Patent: August 27, 2002Inventors: Lieven Meerpoel, Mark Arthur Josepha Van der Flaas, Louis Jozef Elisabeth Van Der Veken, Jan Heeres
-
Patent number: 6441244Abstract: The invention relates to new compounds of the formula (I) in which R is phenyl, C1-4alkyl-, C1-4alkoxy- or halogen-substituted phenyl, naphthyl or an aromatic ring containing heteroatoms; X is O or S; R1 and R2 are each a methyl radical or R1 and R2 together are a C4-8alkylene radical; Y is hydroxyl, C1-12alkoxy, C1-4alkylamino, di-C1-4alkylamino or a piperidine or morpholine ring that is attached by its nitrogen atom; to a process for preparing them and to their use as photoinitiators and/or photosensitizers.Type: GrantFiled: July 12, 2001Date of Patent: August 27, 2002Assignee: Clariant Finance (BVI) LimitedInventors: Lajos Avar, René Bär, Victor Sanahuja
-
Patent number: 6376534Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. Intermediates to the compounds of the formula I are also claimed.Type: GrantFiled: June 1, 2000Date of Patent: April 23, 2002Assignee: Astrazeneca Canada Inc.Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun
-
Patent number: 6350892Abstract: Selective inhibitors of the cPLA2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where (R′), p, D, Y, Z, Ra, Rb and A are as defined in the specification.Type: GrantFiled: February 18, 2000Date of Patent: February 26, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Jacques Banville, Yonghua Gai, Graham Johnson, Fred Christopher Zusi, James R. Burke
-
Publication number: 20020019568Abstract: The invention relates to a process for the enantioselective preparation of tolterodine and analogues and salts thereof comprises the steps of:Type: ApplicationFiled: July 31, 2001Publication date: February 14, 2002Inventors: Pher G. Andersson, Christian Hedberg
-
Patent number: 6331564Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P, the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.Type: GrantFiled: September 23, 1998Date of Patent: December 18, 2001Assignee: Ion Pharmaceuticals, Inc.Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellot, Jr., Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
-
Patent number: 6329399Abstract: Novel amine derivatives having an excellent antimycotic effect represented by general formula (1) below and salts thereof are provided. [in the formula (1, R1 represents a C1-5 alkyl group which may be halogenated, R2 represents 4-(1,1-dimethylalkyl)benzyl group, 4-(1-methyl-phenylethyl)benzyl group, 1-or 2-naphthylmethyl group, or a hydrocarbon group having 3,3-dimethyl-1-butynyl group or a phenyl group at its terminal and 1 to 3 double bonds; R3 represents oxygen atom or a methylene group which may be substituted by a C1-4 alkyl group; and R4 represents 1-or 2 naphthyl group or a phenyl group which may be substituted.Type: GrantFiled: May 18, 2000Date of Patent: December 11, 2001Assignee: Pola Chemical Industries, Inc.Inventors: Takao Itoh, Takuji Nakashima, Akira Nozawa, Kouji Yokoyama, Hiroyuki Takimoto, Masayuki Yuasa, Yukio Kawazu, Toshimitsu Suzuki, Toshiro Majima
-
Patent number: 6313132Abstract: The invention relates to novel compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and Ar are as defined in claim 1, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The compounds have anticholinergic activity, and the invention also relates to the compounds of Formula (I), the use of the compounds of Formula (I) for preparing anticholinergic drugs, the use of the compounds of Formula (I) for treating urinary tract incontinence, and methods for preparing the compounds of Formula (I).Type: GrantFiled: September 27, 1999Date of Patent: November 6, 2001Assignee: Pharmacia ABInventors: Rolf Johansson, Martin Haraldsson, Erik Ringberg, Ian Vagberg, Katarina Beierlein, Rikard Emond, Birger Sjoberg
-
Patent number: 6310103Abstract: The S-isomer of a compound represented by the following formula: and pharmaceutically acceptable salts thereof is disclosed as being useful for treating urinary disorders, including urinary incontinence, and gastrointestinal disorders, including gastrointestinal hyperativity.Type: GrantFiled: January 11, 1999Date of Patent: October 30, 2001Assignee: Bridge Pharma, Inc.Inventor: Gunnar Aberg
-
Patent number: RE39667Abstract: The invention relates to 3,3-diphenylpropylamines of formula (I), wherein R1 signifies hydrogen or methyl, R2 and R3 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula (II), wherein R4 and R5 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R4 and R5 may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.Type: GrantFiled: November 5, 1993Date of Patent: May 29, 2007Assignee: Pfizer Health ABInventors: Rolf A. Johansson, Pinchas Moses, Lisbeth Nilvebrant, Bengt A. Sparf